机构：[1]MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.[2]Chinese Academy of Medical Science Oxford Institute (COI), Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.[3]Department of Liver Surgery and Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院
The prevalence and incidence of cancers has risen over the last decade. Available treatments have improved outcomes, yet mortality and morbidity remain high, creating an urgent demand for personalized and new therapy targets. Interferon induced transmembrane protein (IFITM3) is highly expressed in cancers and is a marker of poor prognosis. In this review, we discuss recent advances in IFITM3 biology, the regulatory pathways, and its function within cancer as part of immunity and maintaining stemness. Overexpression of IFITM3 is likely an indirect effect of ongoing inflammation, immune and cancer epithelial-to-mesenchymal (EMT) related pathways i.e., interferons, TGF-β, WNT/β-catenin, etc. However, IFITM3 also influences tumorigenic phenotypes, such as cell proliferation, migration and invasion. Furthermore, IFITM3 plays a key role in cancer growth and maintenance. Silencing of IFITM3 reduces these phenotypes. Therefore, targeting of IFITM3 will likely have implications for potential cancer therapies.
基金：
UK Medical Research and
Chinese Academy of Medical Sciences (CAMS) Innovation Fund
for Medical Sciences (CIFMS), China (grant number: 2018-I2M-
2-002) and Nuffield Department of Medicine, Oxford University.
Illustrations were created with BioRender (Biorender.com).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版：
大类|3 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.[2]Chinese Academy of Medical Science Oxford Institute (COI), Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
通讯作者：
通讯机构：[1]MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.[2]Chinese Academy of Medical Science Oxford Institute (COI), Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
推荐引用方式(GB/T 7714)：
Rajapaksa Ushani S,Jin Chen,Dong Tao.Malignancy and IFITM3: Friend or Foe?[J].Frontiers in oncology.2020,10:593245.doi:10.3389/fonc.2020.593245.
APA：
Rajapaksa Ushani S,Jin Chen&Dong Tao.(2020).Malignancy and IFITM3: Friend or Foe?.Frontiers in oncology,10,
MLA：
Rajapaksa Ushani S,et al."Malignancy and IFITM3: Friend or Foe?".Frontiers in oncology 10.(2020):593245
